U.S. Non-oncology Biopharmaceuticals Market will generate new growth opportunities 2021-2028 | Sanofi S.A., Pfizer, Inc., Johnson & Johnson, Novartis International AG

U.S. Non-oncology Biopharmaceuticals Market continues to expand with Sanofi completing the acquisition of Kadmon Holdings to strengthen its transplant business

Market Overview

A biopharmaceutical is a medical term that describes any biotechnology-based pharmaceutical product, produced in, created from, or extracted from living cells. This includes living sources like animal tissues, human tissue, and even plants. Biopharmaceutical plants can be strictly biotechnological or they can be strictly pharmaceutical. In some cases, plants are used to create pharmaceutical drugs, but in other instances, drugs are made from plant sources. Non-oncology biopharmaceuticals are used for drug development of various diseases including rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, and osteoporosis.

To Get more Business Statergies Request for Sample Report at – https://www.coherentmarketinsights.com/insight/request-sample/2575

Market Dynamics

Rising product launches and approvals are expected to drive growth of the U.S. non-oncology biopharmaceuticals market during the forecast period. Key companies in the biopharmaceuticals industry are focused on research and development activities, in order to product approval and enhance the market presence. For instance, in April 2020, Banner Life Sciences received the U.S. Food and Drug Administration (FDA) approval for Bafiertam, indicated for the treatment of multiple sclerosis. Therefore, these factors are expected to drive growth U.S. non-oncology biopharmaceuticals market during the forecast period.

However, high price of branded biologic products is expected to hamper the U.S. non-oncology biopharmaceuticals market growth over the forecast period.

Impact of COVID-19

The outbreak of the COVID-19 pandemic has significantly impacted the U.S. non-oncology biopharmaceuticals market. Since the outbreak in December 2019, many countries decided to close down their borders and suspend international travels temporarily, in an attempt to curb the virus. The manufacturing activities across various industries witnessed a significant decline during the pandemic, rendering slow economic growth globally.

To Get Research PDF Brochure Here @ https://www.coherentmarketinsights.com/insight/request-pdf/2575

Key Takeaways

• The U.S. non-oncology biopharmaceuticals market is expected to expand, exhibiting a CAGR of XX% over the forecast period. This is owing to continuous R&D activities in the field of biopharmaceuticals. For instance, in August 2019, AbbVie received the U.S. FDA approval for RINVOQ for the treatment of rheumatoid arthritis.

• Rising mergers and acquisitions among key companies are expected to boost the U.S. non-oncology biopharmaceuticals market growth in the near future. For instance, in September 2021, Sanofi acquired Kadmon Holdings Inc., a biopharmaceutical company, to strengthen its transplant business.

• Key companies involved in the U.S. non-oncology biopharmaceuticals market are Sanofi S.A., Pfizer, Inc., Johnson & Johnson, Novartis International AG, Amgen, Inc., Eli Lilly and Company, AbbVie Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Novo Nordisk A/S, GlaxoSmithKline plc., UCB Pharma, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Ltd, AstraZeneca Plc, and Mylan N.V.

To Direct Purchase this Research Report – https://www.coherentmarketinsights.com/insight/buy-now/2575

Contact Us:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

This release was published on openPR.